Microcap Ledger

Tickers · $INBS

Intelligent BIO Solutions Inc. $INBS

By Microcap Ledger desk · CIK 0001725430

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Surgical & Medical Instruments & Apparatus
Headquarters
New York, NY
Fiscal year end
June 30
Shares outstanding
3,027,470 [10-K 2026-08-19]
as of 2026-08-18

Sources: [10-K 2026-08-19]

What the company doesAI summary of filing

Intelligent Bio Solutions Inc. is a medical technology company that develops and commercializes rapid, non-invasive drug screening and diagnostic testing solutions. The company's primary product is the Intelligent Fingerprinting Drug Screening System, a portable point-of-care device that analyzes fingerprint sweat samples using a single-use cartridge and handheld reader to detect drugs of abuse including opiates, cocaine, methamphetamine, benzodiazepines, cannabis, methadone, and buprenorphine. The system is commercially available in select markets outside the United States, primarily the United Kingdom, Europe, Australia, and other regions, with customers including organizations in safety-critical industries, drug treatment centers, and judicial organizations. The company generates revenue from sales of cartridges and readers to over 502 customers, primarily small to medium-sized businesses, and is pursuing FDA 510(k) clearance for the U.S. market while expanding distribution networks internationally. [10-K 2026-08-19]

Segments: Intelligent Fingerprinting Drug Screening System, Biosensor Platform, SmarTest Patch

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
FY ended Jun 2026$4.22M−$12.43M −$11.93M$3.99M[10-K 2026-08-19]
FY ended Jun 2025$3.05M−$10.57M −$9.68M$1.02M[10-K 2026-08-19]
Quarterly cash burn
−$2.98M
Cash runway Estimate
~4 months

Estimate: cash at the end of the period (FY ended Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-044,386,816[10-Q 2024-11-07]
2025-02-115,278,837[10-Q 2025-02-13]
2025-05-096,910,279[10-Q 2025-05-13]
2025-08-128,979,152[10-K 2025-08-15]
2025-11-109,452,553[10-Q 2025-11-12]
2026-02-121,603,783[10-Q 2026-02-12]
2026-05-122,391,846[10-Q 2026-05-13]
2026-08-183,027,470[10-K 2026-08-19]
Shelf registration
S-3 filed 2026-09-15; declared effective 2026-09-23 [S-3 2026-09-15]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-12-16. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2025-12-168-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-12-16]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-03-18Boyages Steven Constantinegrant5,000—[4 2026-03-20]
2026-03-18Fraser Nicola Mariongrant5,000—[4 2026-03-20]
2026-03-18Sakiris Spiro Kevingrant9,150—[4 2026-03-20]
2026-03-18Sakiris Spiro Kevingrant21,350—[4 2026-03-20]
2026-03-18Hurd Jonathan Scottgrant5,000—[4 2026-03-20]
2026-03-18Isenberg Jasongrant5,000—[4 2026-03-20]
2026-03-18Simeonidis Harrygrant9,150—[4 2026-03-20]
2026-03-18Simeonidis Harrygrant21,350—[4 2026-03-20]

Catalysts and calendar

Facts as of . Small caps move fast; check the latest filings.